Global private equity firms flock to China-based I-Mab

I-Mab Biopharma announced a $418 million private placement deal, with numerous private equity managers joining Hillhouse Capital in supporting the biologics company.

In addition to Hillhouse . . .

Continue Reading With a Free Trial

Unlock this article instantly, along with the rest of our premium content, newsletters and mandate charts.

Already a subscriber? Log in.